| 谭玉靓,樊 英.mTOR抑制剂耐药机制及预测依维莫司疗效标志物的研究进展[J].肿瘤学杂志,2024,30(1):18-24. |
| mTOR抑制剂耐药机制及预测依维莫司疗效标志物的研究进展 |
| Progress on Mechanism of Resistance to mTOR Inhibitor and Predicting Biomarkers for Everolimus Efficacy |
| 投稿时间：2023-08-15 |
| DOI：10.11735/j.issn.1671-170X.2024.01.B005 |
|
 |
| 中文关键词: 乳腺癌 耐药 哺乳动物雷帕霉素靶蛋白抑制剂 依维莫司 疗效标志物 |
| 英文关键词:breast cancer drug resistance mammalian target of rapamycin inhibitor everolimus predictive marker |
| 基金项目:中国医学科学院肿瘤医院内科重点学科发展基金（CICAMS-MOMP2022003） |
|
| 摘要点击次数: 135 |
| 全文下载次数: 66 |
| 中文摘要: |
| 摘 要： 依维莫司是一种哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin，mTOR)抑制剂，可改善晚期激素受体阳性/人表皮生长因子受体2阴性（hormone receptor-positive/human epidermal growth factor receptor 2-negative，HR+/HER2-）乳腺癌患者的预后。然而，依维莫司耐药日益发展，缺乏有效的标志物预测其疗效，对其临床应用造成了挑战。针对这一重要的临床问题，全文整理了近年来mTOR抑制剂的耐药机制及依维莫司疗效预测标志物的相关研究，以期提供参考。 |
| 英文摘要: |
| Abstract： Everolimus， a mammalian target of rapamycin(mTOR) inhibitor， has been shown to improve survival of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. However， resistance to everolimus has been increasingly developed， and there is no efficient biomarker to predict its efficacy， which becomes a challenge for the clinical use of everolimus. This paper reviews the mechanisms of resistance to mTOR inhibitor and potential markers that can predict the efficacy of everolimus. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |